Patents by Inventor Karl-Dimiter BISSIG

Karl-Dimiter BISSIG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN LIVER CHIMERIC NON-HUMAN ANIMAL WITH DEFICIENT P450 OXIDOREDUCTASE AND METHODS OF USING SAME
    Publication number: 20230337643
    Abstract: The present disclosure provides a chimeric non-human animal comprising human hepatocytes, methods for preparing the chimeric non-human animal comprising human hepatocytes and methods of utilizing the chimeric non-human animal comprising human hepatocytes to screening and identifying metabolites for any type of drugs, typically small molecule drugs, which might affect human liver functions and any other bodily function.
    Type: Application
    Filed: June 15, 2023
    Publication date: October 26, 2023
    Applicant: Baylor College of Medicine
    Inventors: Karl-Dimiter BISSIG, Maria DE LAS MERCEDES BARZI DIEGUEZ, Francis Peter PANKOWICZ
  • ANTIBODY BASED GENE THERAPY WITH TISSUE-DIRECTED EXPRESSION
    Publication number: 20230331819
    Abstract: Embodiments of the disclosure include methods and compositions for treatment of a medical condition related to the liver, including at least viral infections and liver cancer, for example. In specific embodiments, immunotherapies are provided for delivering polynucleotides locally to the liver, wherein the polynucleotides encode particular gene products that include bispecific antibodies, including those that target certain liver antigens, for example.
    Type: Application
    Filed: January 30, 2023
    Publication date: October 19, 2023
    Inventors: Robert Layne KRUSE, Karl-Dimiter BISSIG, Stephen M.G. GOTTSCHALK, Thomas C.T. Shum
  • Human liver chimeric mouse with deficient P450 oxidoreductase
    Patent number: 11716974
    Abstract: The present disclosure provides a chimeric non-human animal comprising human hepatocytes, methods for preparing the chimeric non-human animal comprising human hepatocytes and methods of utilizing the chimeric non-human animal comprising human hepatocytes to screening and identifying metabolites for any type of drugs, typically small molecule drugs, which might affect human liver functions and any other bodily function.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: August 8, 2023
    Assignee: Baylor College of Medicine
    Inventors: Karl-Dimiter Bissig, Maria de las Mercedes Barzi Dieguez, Peter Francis Pankowicz
  • Antibody based gene therapy with tissue-directed expression
    Patent number: 11566063
    Abstract: Embodiments of the disclosure include methods and compositions for treatment of a medical condition related to the liver, including at least viral infections and liver cancer, for example. In specific embodiments, immunotherapies are provided for delivering polynucleotides locally to the liver, wherein the polynucleotides encode particular gene products that include bispecific antibodies, including those that target certain liver antigens, for example.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: January 31, 2023
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Robert Layne Kruse, Karl-Dimiter Bissig, Stephen M. G. Gottschalk, Thomas C. T. Shum
  • Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
    Patent number: 11219646
    Abstract: Embodiments of the disclosure encompass immunotherapy for Hepatitis B viral (HBV) infection in an individual in need thereof. The immunotherapy comprises one or more chimeric antigen receptors (CAR) that target a HBV antigen, including CAR molecules that utilize specific scFv antibodies. In certain cases, the CAR comprises one or more mutations to reduce binding to Fc receptors. In specific aspects, cells that express the CAR(s) have reduced cytotoxicity that is safer and/or beneficial to individuals that are immunocompromised.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: January 11, 2022
    Assignee: Baylor College of Medicine
    Inventors: Robert Layne Kruse, Karl-Dimiter Bissig, Stephen M. G. Gottschalk, Thomas C. T. Shum
  • CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
    Publication number: 20190307798
    Abstract: Embodiments of the disclosure encompass immunotherapy for Hepatitis B viral (HBV) infection in an individual in need thereof. The immunotherapy comprises one or more chimeric antigen receptors (CAR) that target a HBV antigen, including CAR molecules that utilize specific scFv antibodies. In certain cases, the CAR comprises one or more mutations to reduce binding to Fc receptors. In specific aspects, cells that express the CAR(s) have reduced cytotoxicity that is safer and/or beneficial to individuals that are immunocompromised.
    Type: Application
    Filed: September 29, 2017
    Publication date: October 10, 2019
    Inventors: Robert Layne Kruse, Karl-Dimiter Bissig, Stephen M. G. Gottschalk, Thomas C. T. Shum
  • ANTIBODY BASED GENE THERAPY WITH TISSUE-DIRECTED EXPRESSION
    Publication number: 20190225673
    Abstract: Embodiments of the disclosure include methods and compositions for treatment of a medical condition related to the liver, including at least viral infections and liver cancer, for example. In specific embodiments, immunotherapies are provided for delivering polynucleotides locally to the liver, wherein the polynucleotides encode particular gene products that include bispecific antibodies, including those that target certain liver antigens, for example.
    Type: Application
    Filed: September 29, 2017
    Publication date: July 25, 2019
    Inventors: Robert Layne Kruse, Karl-Dimiter Bissig, Stephen M. G. Gottschalk, Thomas C. T. Shum
  • HUMAN LIVER CHIMERIC NON-HUMAN ANIMAL WITH DEFICIENT P450 OXIDOREDUCTASE AND METHODS OF USING SAME
    Publication number: 20190166810
    Abstract: The present disclosure provides a chimeric non-human animal comprising human hepatocytes, methods for preparing the chimeric non-human animal comprising human hepatocytes and methods of utilizing the chimeric non-human animal comprising human hepatocytes to screening and identifying metabolites for any type of drugs, typically small molecule drugs, which might affect human liver functions and any other bodily function.
    Type: Application
    Filed: June 27, 2017
    Publication date: June 6, 2019
    Inventors: Karl-Dimiter BISSIG, Maria de las Mercedes Barzi DIEGUEZ, Peter Francis PANKOWICZ